Chongqing Xishan Science&Technology Co. Ltd. A

688576 · SHG · Healthcare / Medical Instruments & Supplies

34.94CNY-0.22 (-0.63%)

Price History

Full chart

Market Stats

Previous Close35.16

Open35.08

Day Range34.90 – 35.77

52-Week Range34.83 – 58.22

Volume279.95K

Market Cap2.70B

P/E (TTM)0.00

Forward P/E0.00

EPS-0.12

Dividend Yield1.25%

Beta1.01

50-Day Avg39.49

200-Day Avg45.73

About

Chongqing Xishan Science & Technology Co., Ltd. engages in the research and development, manufacturing, sale, and service of digital minimally invasive surgical equipment and medical consumables in China and internationally. The company offers powered surgical instruments, such as micromotor, handpiece, attachment, shaver, bur, saw blade, and perforator; vacuum-assisted breast biopsy, including control module, handpiece, probe, and canister. It also provides UHD endocsopy systems comprising camera control unit, camera head, light source unit, LCD monitor, transforaminal endoscope, arthroscope, laparoscope, and trolley; ultrasonic bone scalpel systems; RF/HF electrosurgical unit and surgical electrode; and plasma electrosurgical unit and plasma surgical electrode. The company was founded in 1999 and is headquartered in Chongqing, China.

Company Details

SectorHealthcare
IndustryMedical Instruments & Supplies
CEOMr. Yijun Guo
Employees837
HeadquartersNo. 2, Kangzhu Road, Chongqing, China, 401123, China
Websitehttps://www.xishantech.com.cn

Leadership

Mr. Yijun GuoChairman of the Board & General Manager · b. 1965
Ms. Xue BaiFinancial Director, Secretary of the Board & Director · b. 1985
Ms. Airong HeHuman Resources Director · b. 1981
Mr. Xi LiangDeputy GM & Director · b. 1971
Ms. Changying WangDeputy GM & Director · b. 1981
Mr. Zhu ChenDeputy General Manager · b. 1982

Financials

Income Statement

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	208.86M	262.27M	360.69M	336.38M	341.99M
Growth (%)	-	+25.57%	+37.52%	-6.74%	+1.67%
Cost of Revenue	63.36M	82.45M	111.88M	99.48M	124.14M
Gross Profit	145.50M	179.83M	248.80M	236.90M	217.85M
Gross Margin	69.67%	68.56%	68.98%	70.43%	63.70%
Operating Expense	90.17M	109.70M	139.60M	161.63M	177.52M
Operating Income	55.34M	70.12M	109.20M	75.27M	40.33M
Operating Margin	26.50%	26.74%	30.28%	22.38%	11.79%
EBITDA	-	83.84M	137.78M	125.33M	66.01M
EBITDA Margin	-	31.97%	38.20%	37.26%	19.30%
Net Income	61.43M	75.35M	117.34M	98.67M	51.91M
Net Income Margin	29.41%	28.73%	32.53%	29.33%	15.18%
R&D	28.09M	29.94M	46.50M	55.24M	58.08M
R&D as % of Total Revenue	13.45%	11.42%	12.89%	16.42%	16.98%
Interest Expense	441.41K	364.49K	202.27K	51.65K	-
Interest Expense % of Total Revenue	0.21%	0.14%	0.06%	0.02%	-

Balance Sheet

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	403.58M	522.66M	2.32B	1.93B	1.90B
Total Liabilities	77.93M	116.17M	157.41M	160.75M	170.74M
Total Equity	325.65M	406.49M	2.16B	1.77B	1.73B
Cash	304.24M	332.89M	712.25M	558.45M	289.08M

Cash Flow

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	55.88M	79.10M	68.08M	39.47M	60.03M
Capital Expenditure	14.18M	49.15M	103.72M	157.55M	96.00M
Free Cash Flow	41.70M	29.95M	-35.64M	-118.08M	-35.96M
Dividends Paid	29.72K	-	-	48.88M	45.19M
FCF to OCF	74.62%	37.86%	-52.35%	-299.18%	-59.90%
Dividend Paid to FCF	0.07%	-	-	-41.40%	-125.66%

Key Statistics & Ratios

Market Cap2.70B

Enterprise Value2.05B

Trailing P/E0.00

Forward P/E0.00

Price / Sales8.79

Price / Book1.65

EPS-0.12

Book Value25.45

Revenue (TTM)306.53M

Gross Profit (TTM)172.95M

EBITDA-9.89M

Profit Margin-2.59%

Operating Margin-88.15%

Return on Equity-0.47%

Return on Assets-1.16%

Shares Outstanding67.64M

Shares Float38.27M

Beta1.01

Dividend Yield1.25%

Dividend Rate0.50

Payout Ratio92.59%

Dividends

20261×

0.50Jun 23, 2026

20251×

0.67Jun 25, 2025

20241×

0.67Aug 22, 2024

Stock Splits

Jun 23, 20261.49:1